Author information from the last article
Arne Kolstad (f. 1958) er spesialist i onkologi og overlege.
Forfatter har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
Avdeling for kreftbehandling
Oslo universitetssykehus, Rikshospitalet
Articles by Arne Kolstad
High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Alexander Fosså,
- Jens Hammerstrøm,
- Vidar Jetne,
- Arne Kolstad,
- Gunnar Kvalheim,
- Jon Håvard Loge,
- Turid Løkeland,
- Jon Magnus Tangen,
- Harald Holte,
- Stein Kvaløy
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) for lymphomas has been given in Norway since 1987. The therapy consists of intensive chemotherapy and/or total body irradiation in such high doses that it entails a life-threatening loss of healthy haematopoietic stem cells in the bone marrow...
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987 – 2008
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Anne Kirsti Blystad,
- Unn Merete Fagerli,
- Øystein Fluge,
- Alexander Fosså,
- Jens Hammerstrøm,
- Arne Kolstad,
- Jon Håvard Loge,
- Martin Maisenhølder,
- Bjørn Østenstad,
- Stein Kvaløy,
- Harald Holte
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) is a very intensive, highly specialised and resource-intensive therapy. It has been a treatment option for lymphomas for 25 years. Based on results from prospective studies, it has progressed from being an experimental form of treatment to...